Online citations, reference lists, and bibliographies.
← Back to Search

New Markers For Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?

A. Churg, B. Sheffield, F. Galateau-Sallé
Published 2016 · Biology, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
CONTEXT The separation of benign from malignant mesothelial proliferations is crucial to patient care but is frequently morphologically difficult. OBJECTIVE To briefly review adjunctive tests claimed to be useful in this setting and to examine in detail 2 new tests: p16 fluorescence in situ hybridization (FISH) and BRCA1-associated protein 1 (BAP1) immunohistochemistry. DESIGN Literature review with emphasis on p16 FISH and BAP1 immunohistochemistry. RESULTS Glucose transporter-1, p53, insulin-like growth factor 2 messenger RNA-binding protein 3 (IMP-3), desmin, and epithelial membrane antigen have all been claimed to mark either benign or malignant mesothelial processes, but in practice they at best provide statistical differences in large series of cases, without being useful in an individual case. Homozygous deletion of p16 by FISH or loss of BAP1 has only been reported in malignant mesotheliomas and not in benign mesothelial proliferations. BAP1 appears to be lost more frequently in epithelial than mixed or sarcomatous mesotheliomas. Homozygous deletion of p16 by FISH is seen in pleural epithelial, mixed, and sarcomatous mesotheliomas, but it is much less frequent in peritoneal mesothelioma. The major drawback to both these tests is limited sensitivity; moreover, failure to find p16 deletion or BAP1 loss does not make a mesothelial process benign. CONCLUSIONS In the context of a mesothelial proliferation, the finding of homozygous deletion of p16 by FISH or loss of BAP1 by immunohistochemistry is, thus far, 100% specific for malignant mesothelioma. The limited sensitivity of each test may be improved to some extent by running both tests.
This paper references
10.1309/AJCPT94JVWIHBKRD
Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis.
D. Wu (2013)
10.1046/j.1365-2559.2003.01686.x
The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet‐derived growth factor‐receptor, P‐glycoprotein and Bcl‐2
R. Attanoos (2003)
10.1200/JCO.1998.16.3.1197
Role of the p16 tumor suppressor gene in cancer.
W. Liggett (1998)
Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports. Histopathology
J King (2006)
10.1002/ijc.27316
Cellular senescence and tumor suppressor gene p16
H. Rayess (2012)
10.1111/j.1365-2559.2006.02442.x
Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports
J. King (2006)
10.1371/journal.pone.0035295
Germline BAP1 Inactivation Is Preferentially Associated with Metastatic Ocular Melanoma and Cutaneous-Ocular Melanoma Families
C. Njauw (2012)
Implications of P 16 / CDKN 2 A deletion in pleural mesotheli - omas
M Ladanyi (1998)
10.5858/arpa.2012-0112-ra
The Separation of Benign and Malignant Mesothelial Proliferations
A. Churg (2012)
10.1016/J.LUNGCAN.2005.03.017
Implications of P16/CDKN2A deletion in pleural mesotheliomas.
M. Ladanyi (2005)
10.1111/j.1349-7006.2012.02223.x
Frequent inactivation of the BAP1 gene in epithelioid‐type malignant mesothelioma
Yoshie Yoshikawa (2012)
10.5858/arpa.2011-0219-OA
Utility of glucose transporter 1 in the distinction of benign and malignant thoracic and abdominal mesothelial lesions.
S. Lagana (2012)
10.1097/PAT.0000000000000250
Loss of expression of BAP1 predicts longer survival in mesothelioma
M. Farzin (2015)
10.1309/AJCP5KNL7QTELLYI
Comparative immunohistochemical analysis of IMP3, GLUT1, EMA, CD146, and desmin for distinguishing malignant mesothelioma from reactive mesothelial cells.
H. Minato (2014)
10.1038/modpathol.2008.45
Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas
S. Chiosea (2008)
10.1038/modpathol.2009.186
CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival
A. Krasinskas (2010)
10.1097/PAS.0b013e318218985b
Oncofetal Protein IMP3, a New Diagnostic Biomarker to Distinguish Malignant Mesothelioma From Reactive Mesothelial Proliferation
M. Shi (2011)
10.1038/modpathol.2015.65
BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations
Marta Cigognetti (2015)
10.1111/j.1365-2559.2011.03907.x
Patterns of p53 immunoreactivity in endometrial carcinomas: ‘all or nothing’ staining is of importance
W. G. McCluggage (2011)
10.1158/0008-5472.CAN-14-1008
Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma.
Guangwu Guo (2015)
10.1007/s00428-008-0689-3
Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas
S. Dacic (2008)
10.1111/j.1365-2559.2010.03715.x
Novel staining pattern of p53 in Barrett’s dysplasia – the absent pattern
P. Kaye (2010)
10.1093/CARCIN/23.7.1127
Alterations of the p16(INK4) locus in human malignant mesothelial tumors.
T. Hirao (2002)
10.1016/j.ygyno.2008.09.013
Pitfalls in immunohistochemical validation of tumor marker expression--exemplified in invasive cancer of the uterine cervix.
D. Hellberg (2009)
p 16 / CDKN 2 A FISH in differentiation of diffuse malignant peritoneal mesothelioma from mesothelial hyperplasia and epithelial ovarian cancer
T Ito (2015)
10.1309/AJCPOATJ9L4GCGDA
p16/CDKN2A FISH in Differentiation of Diffuse Malignant Peritoneal Mesothelioma From Mesothelial Hyperplasia and Epithelial Ovarian Cancer.
T. Ito (2015)
10.1038/ng.912
Germline BAP1 mutations predispose to malignant mesothelioma
J. Testa (2011)
10.1038/modpathol.3800732
Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma
Y. Kato (2007)
10.1200/JCO.2009.23.9640
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience.
T. Yan (2009)
10.1097/PAS.0b013e31826ab1c0
IMP3 and GLUT-1 Immunohistochemistry for Distinguishing Benign From Malignant Mesothelial Proliferations
A. Lee (2013)
Diagnostic importance of 9 p 21 homozygous deletion in malignant mesothelio
S Chiosea (2003)
10.5858/arpa.2012-0108-OA
p16 Deletion in sarcomatoid tumors of the lung and pleura.
N. Tochigi (2013)
10.1309/AJCPWFW7O1FVFLKT
Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids.
J. Shen (2009)
10.1097/PAS.0000000000000394
BAP1 Immunohistochemistry and p16 FISH to Separate Benign From Malignant Mesothelial Proliferations
B. Sheffield (2015)
10.1111/j.1440-1827.2010.02534.x
9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis
M. Takeda (2010)
10.1097/JTO.0000000000000471
High Incidence of Somatic BAP1 Alterations in Sporadic Malignant Mesothelioma
Masaki Nasu (2015)
Epithelioid mesothelioma
F Galateau-Salle (2015)
10.1111/pin.12216
Practical utility of insulin‐like growth factor II mRNA‐binding protein 3, glucose transporter 1, and epithelial membrane antigen for distinguishing malignant mesotheliomas from benign mesothelial proliferations
S. Chang (2014)
10.1038/ng.855
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma
Matthew J Bott (2011)
BAP 1 ( BRCA 1 - associated protein 1 ) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations . Mod Pathol
M Cigognetti (2012)
Tumours associated with BAP 1 mutations
R Murali (2011)
10.1097/PAT.0b013e32835d0efb
Tumours associated with BAP1 mutations
R. Murali (2013)
10.1097/PAS.0000000000000176
p16 FISH Deletion in Surface Epithelial Mesothelial Proliferations Is Predictive of Underlying Invasive Mesothelioma
H. Hwang (2014)
10.1002/cncr.10923
The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions
P. Illei (2003)
10.1136/jclinpath-2012-201303
Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers
D. Henderson (2013)
10.1136/jcp.2010.076794
FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma
C. Chung (2010)
10.1309/AJCPP5R2ZJZKCLWN
The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations.
S. Monaco (2011)
Tumours associated with BAP1 mutations. Pathology
R Murali (2013)
10.1158/1078-0432.CCR-11-2375
New Strategies in Pleural Mesothelioma: BAP1 and NF2 as Novel Targets for Therapeutic Development and Risk Assessment
M. Ladanyi (2012)



This paper is referenced by
10.21037/tlcr.2017.05.06
Diagnostic and prognostic biomarkers for malignant mesothelioma: an update.
Z. Chen (2017)
10.1111/pin.12973
Genomic‐based ancillary assays offer improved diagnostic yield of effusion cytology with potential challenges in malignant pleural mesothelioma
Yoshiaki Kinoshita (2020)
10.21037/jtd.2017.10.125
The pathological and molecular diagnosis of malignant pleural mesothelioma: a literature review.
G. Alí (2018)
10.1093/ejcts/ezy258
ERS/EACTS statement on the management of malignant pleural effusions
A. Bibby (2019)
10.3322/caac.21572
Mesothelioma: Scientific clues for prevention, diagnosis, and therapy
M. Carbone (2019)
10.1111/crj.12982
Pleura revisited: From histology and pathophysiology to pathology and molecular biology
G. Karpathiou (2019)
10.1183/13993003.00349-2018
ERS/EACTS statement on the management of malignant pleural effusions
A. Bibby (2018)
10.4103/cytojournal.cytojournal_54_16
A diagnostically difficult case of a cellular pleural fluid: Morphology, immunohistochemistry, and fluorescence in situ hybridization study
M. Wang (2017)
10.1016/j.ejso.2017.05.009
Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: A RENAPE study.
S. Valmary-Degano (2017)
10.1002/pbc.28286
Multicystic and diffuse malignant peritoneal mesothelioma in children
Sophie Vermersch (2020)
10.1097/PAS.0000000000001565
The Separation of Benign and Malignant Mesothelial Proliferations
A. Churg (2020)
10.1111/pin.12990
Utility of highly expressed EZH2 in pleural effusion cytology for the diagnosis of mesothelioma
M. Yoshimura (2020)
Pathology International
S. Noriki (2019)
10.1002/cncy.22221
Usefulness of methylthioadenosine phosphorylase and BRCA‐associated protein 1 immunohistochemistry in the diagnosis of malignant mesothelioma in effusion cytology specimens
Kyra B. Berg (2019)
10.3892/ol.2018.7765
Utility of Survivin, BAP1, and Ki-67 immunohistochemistry in distinguishing epithelioid mesothelioma from reactive mesothelial hyperplasia
K. Kushitani (2018)
10.1007/s12024-019-00110-9
The forensic significance of pseudomesotheliomatous adenocarcinoma of the lung
J. Kennedy (2019)
10.1016/j.jtho.2018.04.023
New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi‐Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center
F. Sallé (2018)
10.1007/978-3-319-53577-7_15
Markers and Immunoprofile of Mesothelioma Tumors of the Peritoneum
Muin S. A. Tuffaha (2018)
10.5858/arpa.2019-0370-OA
Use of Programmed Death Ligand-1 (PD-L1) Staining to Separate Sarcomatoid Malignant Mesotheliomas From Benign Mesothelial Reactions.
F. Derakhshan (2019)
10.1016/j.pathol.2016.03.005
Loss of expression of BAP1 is very rare in non-small cell lung carcinoma.
J. Andrici (2016)
10.1097/MNM.0000000000000649
The role of 18F-FDG-PET/ceCT in peritoneal mesothelioma
J. Dubreuil (2017)
10.1007/978-3-030-36438-0_12
Malignant Epithelial Tumors of the Lung
A. Weissferdt (2020)
10.20892/j.issn.2095-3941.2017.0169
Post-irradiation pericardial malignant mesothelioma with deletion of p16: a case report
Yalda B. Naeini (2018)
10.1007/s12253-020-00793-4
Correction to: Monoclonal Caveolin 1 Expression in the Differential Diagnosis of Malignant Pleural Mesothelioma and Pulmonary Adenocarcinoma: Is it Useful?
Zehra Bozdağ (2020)
10.1016/J.JASC.2019.07.005
Proceedings of the American Society of Cytopathology companion session at the 2019 United States and Canadian Academy of Pathology Annual meeting, part 2: effusion cytology with focus on theranostics and diagnosis of malignant mesothelioma.
M. Siddiqui (2019)
10.1002/dc.24315
A case of malignant mesothelioma pleural effusion with MOC‐31, BerEP4, and calretinin expression
Po Zhao (2019)
10.5858/arpa.2016-0073-OA
Dataset for Reporting of Malignant Mesothelioma of the Pleura or Peritoneum: Recommendations From the International Collaboration on Cancer Reporting (ICCR).
A. Churg (2016)
10.21037/amj.2020.02.04
Malignant pleural effusion and mesothelioma
D. Subotic (2020)
10.5858/arpa.2018-0020-RA
Cytopathologic Diagnosis of Epithelioid and Mixed-Type Malignant Mesothelioma: Ten Years of Clinical Experience in Relation to International Guidelines.
A. Hjerpe (2018)
What's new in mesothelioma.
V. Ascoli (2018)
10.1016/j.humpath.2016.10.005
Loss of BRCA1-associated protein 1 (BAP1) expression is rare in non-small cell lung cancer.
D. Owen (2017)
10.1007/978-3-030-16884-1_8
Tissue and Circulating Biomarkers in Mesothelioma
Paolo Andrea Zucali (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar